CTLA-4 is a target for cancer immunotherapy, specifically in the form of immune checkpoint inhibitors. Drugs like ipilimumab block CTLA-4, preventing it from sending inhibitory signals to T cells. This enhances the immune response against cancer cells, making it a promising therapeutic approach in treating various malignancies.
